Search

Your search keyword '"Gomez-Almaguer, D"' showing total 160 results

Search Constraints

Start Over You searched for: Author "Gomez-Almaguer, D" Remove constraint Author: "Gomez-Almaguer, D"
160 results on '"Gomez-Almaguer, D"'

Search Results

1. Guidelines for the management of coagulation disorders in patients with cirrhosis

2. Guías del manejo de trastornos de coagulación en pacientes con cirrosis

3. Blood transfusion in children at a university hospital in a middle-income country: The need to reinforce adherence to current guidelines

8. Latin America: the next region for haematopoietic transplant progress

9. PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY

12. PB1982: DEEPENING OF RESPONSE IN PATIENTS WITH MULTIPLE MYELOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTRIC STUDY IN A LATINO POPULATION

14. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial

15. Hematopoietic stem cell transplant activity in Latin America: Predominant increase in autologous and modest increase in allogeneic HCT with high use of unrelated cord blood grafts: 402

17. Observational study of multiple myeloma in Latin America: 302

20. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.

21. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

22. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

24. Erratum: Latin America: the next region for haematopoietic transplant progress

27. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

28. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts

29. Radiotherapeutic Techniques in Allogeneic Hematopoietic Cell Transplant (HCT)

30. Trends in Utilization of Total Body Irradiation (TBI) Prior to Hematopoietic Cell Transplantation (HCT) Worldwide

32. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease

33. TP2 Patrones De Tratamiento De La Leucemia Mieloide Crónica (Lmc) En Pacientes Resistentes O Intolerantes A Imatinib En Instituciones De Salud Pública En México

34. PSY24 COST OF CARE FOR CHRONIC MYELOID LEUKEMIA (CML) IN PATIENTS EXPERIENCING RESISTANCE AND/OR INTOLERANCE TO IMATINIB FROM THE PUBLIC HEALTH SYSTEM PERSPECTIVE IN MEXICO

35. Reduced-Intensity Allogeneic Versus Autologous Peripheral Blood Stem Cell Transplantation In Patients With Hodgkin's and Non-Hodgkin's Lymphoma

37. 157: Therapeutic Choices in Patients with Ph1 (+) Chronic Myelogenous Leukemia Living in Developing Countries in the Tyrosine Kinase Inhibitors (TKI) Era: Stem Cell Transplantation or TKI?

38. Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience

44. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: The Mexican experience

45. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: results of a prospective, multicenter study

Catalog

Books, media, physical & digital resources